Table 1

Visit schedule

InformationScreeningEnrolmentPreallocation-------AllocationPostallocation-------------End of trial-Off-treatment follow-up
Visit name −Ty−Tz−Tx−T8-T7-T6-T5-T4-T3-T2-T1T0T1T2T3T4T5T6T7T8T9T10T11T12T13T14T15TxTz
Week no. XXX−8−7−6−5−4−3−2−1024681216202428323640444852X64
Information and screening
Motivation appraisalX
Exchange of informationX
Eligibility screening and consentX
X-ray and physical examinationX
Blood testing and urine stickX
Medical and medication historyX
KOOS pain, WOMAC pain, C-SSRS and PHQ-9X
Vital signs, height, body weight and ECGX
Intervention
IDIXXXXXXXX
TDIXXXXX
Lira 3 mg OR Lira 3 mg pboXXXXXXXXXXXXXXXX
Assessments
Physical examinationXXXX
Dietician (group session)XXXXXXXXXXXXX
Titration visit (MD)XXXXX(X)(X)
Medical historyX
Update of medical historyXXX
Medication historyXXXXXXXXXXXXXXXXXX
KOOS, WOMAC, SF-36, IWQoL-lite and O-O resp. crit.XXXX
ICOAPXXXXXXXXXXXXXXXXXX
KOOS pain and WOMAC painXXXXXXXXXXXXXX
C-SSRSXXXXXXXXXXXXXXXXXXX
PHQ-9 and BESXXXXX
TRIM-WeightXXXXXXXXXXXXXXXX
Adverse events report formXXXXXXXXXXXXXXXXXXXXXXXXXX
Vital signs and waist and hip circumferencesXXXXXXXXXXXXXXXXXX
Body weightXXXXXXXXXXXXXXXXXXXXXXXXXXX
Blood testing, height and DXAXXXX
X-rayXXX
ECGXXXXX
Medicine hand-outXXXXXXXXXXXXXXX
Adherence assessmentXXXXXXXXXXXXXXXX
  • BES, Binge Eating Scale; C-SSRS, Columbia Suicide Severity Rating Scale; ICOAP, Intermittent and Constant Osteoarthritis Pain; IDI, intensive dietary intervention; IWQoL-Lite, Impact of Weight on Quality of Life-Lite; KOOS, Knee Injury and Osteoarthritis Outcome Score; Lira, liraglutide; O-O resp. crit., OMERACT-OARSI responder criteria; pbo, placebo; PHQ-9, Patient   Health Questionnaire-9; SF-36, SF-36, Short Form 36; TDI, tapering dietary intervention; TRIM-Weight, Treatment-Related Impact Measure-Weight; WOMAC, Western Ontario and McMaster Universities Arthritis Index.